Indonesia Human Insulin Market By Device (Pens, Syringes, Others); By Indication (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes); By Insulin (Rapid-acting Insulin, Short-acting Insulin, Intermediate-acting Insulin, Others); By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Price: $2699
Published: | Report ID: 89940 | Report Format : Excel, PDF
Indonesia Human Insulin market size was valued at USD 128.30 million in 2023 and is anticipated to reach USD 181.63 million by 2032, at a CAGR of 3.92% during the forecast period (2023-2032).
The Indonesian human insulin market is driven by factors such as the increasing prevalence of diabetes, rising healthcare awareness, and government initiatives to improve diabetes care. With a growing diabetic population, the demand for affordable and accessible insulin products is on the rise. Technological advancements in insulin delivery devices, such as insulin pens and pumps, are contributing to market growth by improving patient convenience and adherence to treatment. Additionally, the increasing focus on healthcare infrastructure and the expansion of insurance coverage for diabetes-related treatments further support market expansion. The rising trend of self-management of diabetes, driven by better patient education and access to healthcare information, is also positively influencing the market. Key market players are focusing on innovation and local production to meet the needs of the growing population and enhance market penetration. These factors, combined with a supportive regulatory environment, contribute to the growth of the human insulin market in Indonesia.
Geographical analysis of Indonesia’s human insulin market highlights a concentration of demand in urbanized regions such as Java, where healthcare infrastructure is more advanced and diabetes awareness is higher. Other regions like Sumatra, Kalimantan, and Sulawesi are gradually increasing their insulin consumption, driven by improving healthcare access and rising diabetes rates. The market is also influenced by key players such as Novo Nordisk, a global leader in insulin production, and Eli Lilly and Company, which provides a range of diabetes care products. Local players like Bio Farma are also crucial in ensuring the availability of insulin, especially in remote areas, while multinational companies such as Pfizer and Wockhardt contribute to the competitive landscape. These companies, along with regional players, play a significant role in shaping the dynamics of insulin distribution and availability across Indonesia.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research!
The Indonesia human insulin market was valued at USD 128.30 million in 2023 and is projected to reach USD 181.63 million by 2032, growing at a CAGR of 3.92% during the forecast period (2023-2032).
The global human insulin market was valued at USD 21,000 million in 2023 and is projected to reach USD 31,208 million by 2032, growing at a CAGR of 4.50% from 2023 to 2032.
Increasing prevalence of diabetes due to lifestyle changes and an aging population is a key driver of market growth.
Rising awareness and access to healthcare, along with government initiatives, are boosting insulin demand in Indonesia.
The market is trending towards more affordable insulin products, including biosimilars, to meet the growing demand.
Competitive analysis reveals strong market participation from global players like Novo Nordisk, Eli Lilly, and local manufacturers like Bio Farma.
Market restraints include limited access to insulin in remote regions and the high cost of some insulin types.
Regional analysis shows the highest demand in urban areas such as Java, with emerging growth in Sumatra, Kalimantan, and Sulawesi.
Report Scope
This report segments the Indonesia Human Insulin Market as follows:
Market Drivers
Rising Prevalence of Diabetes
The increasing prevalence of diabetes in Indonesia is a significant driver for the human insulin market. For instance, Indonesia has the fifth highest number of adults (20-79 years) with diabetes globally, with 20.4 million cases reported in 2024. This rising number of diabetic patients directly translates into an increased demand for insulin products. Diabetes is becoming a major public health concern due to lifestyle changes, including unhealthy diets, lack of physical activity, and genetic factors. As the population continues to age and the burden of chronic diseases grows, the demand for insulin is expected to rise proportionally. Consequently, the market for human insulin is poised for consistent growth to meet the needs of this expanding diabetic population.
Government Initiatives and Healthcare Reforms
Government initiatives aimed at improving healthcare access and quality are playing a crucial role in driving the demand for human insulin in Indonesia. For instance, the Indonesian government has introduced public health campaigns and healthcare subsidies to improve diabetes management. Furthermore, the expansion of healthcare insurance coverage and the introduction of subsidies for diabetes treatments have made insulin more accessible and affordable for the broader population. These efforts have increased the availability of diabetes care, improving the uptake of insulin products across the country. As the government continues to prioritize healthcare reform, insulin demand is expected to grow, supported by favorable policy measures.
Technological Advancements in Insulin Delivery Devices
Technological advancements in insulin delivery systems are driving the growth of the human insulin market in Indonesia. Innovations such as insulin pens, pumps, and smart devices have made insulin administration easier and more efficient. These devices offer greater accuracy, convenience, and comfort, leading to improved patient adherence to prescribed treatments. Moreover, the increasing focus on personalized diabetes management has prompted the development of advanced insulin formulations that cater to specific patient needs. As more individuals turn to advanced insulin delivery methods, the demand for human insulin products is expected to rise. The adoption of digital health tools that allow for remote monitoring and management of insulin therapy also supports the growing trend of self-management in diabetes care.
Increasing Focus on Patient Education and Self-Management
The growing trend of self-management of diabetes is another critical factor contributing to the expansion of the human insulin market in Indonesia. As healthcare awareness improves, more diabetic patients are becoming proactive in managing their condition through lifestyle changes, proper nutrition, and regular use of insulin. Educational campaigns by healthcare providers and non-governmental organizations have empowered patients to take control of their health, leading to a higher demand for insulin products. This shift toward self-management is also supported by increased access to healthcare information and resources, including mobile health applications, online support groups, and educational workshops. The desire for more autonomy in diabetes management is likely to drive continuous growth in the demand for insulin, particularly in urban areas where access to healthcare is more widespread.
Market Trends
Advancements in Insulin Delivery Devices
Technological innovations in insulin delivery devices are significantly influencing the human insulin market in Indonesia. For instance, insulin pens, pumps, and continuous glucose monitors (CGMs) are transforming diabetes management by offering greater accuracy, convenience, and comfort. Traditional insulin syringes are being replaced by more advanced devices, such as insulin pens and prefilled syringes, which offer greater precision and ease of use. These devices are particularly advantageous for patients who require multiple daily insulin injections, as they simplify the injection process and improve patient compliance with their treatment regimens. The growing adoption of these user-friendly delivery systems is enhancing the overall experience for patients with diabetes, improving both adherence to insulin therapy and quality of life. Furthermore, innovations like insulin pumps and smart insulin devices that provide real-time monitoring and automated insulin delivery are gaining traction. As these advanced devices become more accessible, they are expected to drive market growth by making insulin therapy more effective and less burdensome for patients.
Expansion of Diabetes Management Programs
The Indonesian government and healthcare providers are increasingly focusing on the expansion of diabetes management programs, which is further driving the demand for insulin. For instance, national health initiatives and educational campaigns are improving patient awareness and adherence to insulin therapy. These programs are aimed at educating patients on proper insulin use, blood glucose monitoring, and lifestyle modifications to manage their condition effectively. Healthcare facilities and community health initiatives are working to improve patient awareness, ensuring that individuals with diabetes are better equipped to manage their disease and adhere to prescribed treatments. By emphasizing the importance of consistent insulin therapy and offering educational resources, these programs play a crucial role in improving health outcomes and reducing the burden of diabetes in the population. Additionally, the rising emphasis on diabetes management programs is fostering a more proactive approach to disease care, contributing to a growing patient base that is more likely to invest in the necessary insulin products. This expansion is expected to be a key driver in the future growth of the human insulin market in Indonesia.
Shift Toward Long-Acting Insulin Formulations
One of the prominent trends in the Indonesian human insulin market is the increasing adoption of long-acting insulin formulations. These insulins are designed to provide a steady release of insulin over an extended period, typically 24 hours, making them highly effective for patients who require consistent blood glucose control throughout the day. Long-acting insulins, such as insulin glargine and insulin detemir, are increasingly preferred due to their convenience, as they reduce the frequency of injections and help improve overall patient adherence to treatment. For patients with type 2 diabetes, who often struggle with fluctuating blood glucose levels, these formulations provide more stable control, making diabetes management easier and more efficient. As healthcare providers continue to emphasize patient convenience and long-term health outcomes, the demand for long-acting insulin in Indonesia is expected to rise, further shaping the landscape of the market.
Rise of Biosimilar Insulin Products
Another significant market trend is the growing popularity of biosimilar insulin products in Indonesia. Biosimilars are highly similar to branded insulins in terms of their efficacy, safety, and quality, but they are sold at a lower price point. This cost-effective nature makes them an attractive option for both patients and healthcare systems, especially in regions with a high prevalence of diabetes where affordability is a key concern. The introduction of biosimilars has increased competition in the insulin market, providing more options to patients, especially in lower-income segments. As the Indonesian government and healthcare providers continue to focus on increasing access to essential medications, biosimilar insulins are expected to play a crucial role in expanding insulin availability and reducing the financial burden of diabetes treatment for the broader population. This trend also aligns with the increasing emphasis on cost-efficient healthcare solutions across Southeast Asia.
Market Challenges Analysis
Affordability and Accessibility Issues
One of the primary challenges facing the human insulin market in Indonesia is the affordability and accessibility of insulin products. For instance, a study found that a low-income person in Indonesia must work 2–3 days to afford 1000IU of analogue insulin, highlighting the financial burden of diabetes treatment. While the demand for insulin continues to rise due to the increasing prevalence of diabetes, many individuals in rural and low-income areas still struggle to afford the medication. Despite efforts by the government to provide subsidies and expand healthcare insurance coverage, insulin remains costly for a significant portion of the population, particularly for those who require long-term treatment. The lack of widespread access to healthcare facilities and pharmacies, especially in remote regions, further exacerbates the problem. As a result, many patients either delay treatment or do not have access to the necessary insulin doses to manage their condition effectively. This creates a barrier to optimal diabetes care and undermines the overall effectiveness of insulin therapy in improving health outcomes.
Limited Awareness and Education on Diabetes Management
Another challenge for the human insulin market in Indonesia is the limited awareness and education about proper diabetes management, which directly affects patient adherence to insulin therapy. Many individuals with diabetes lack sufficient knowledge about the importance of regular insulin use, proper storage, and dosage. Additionally, misconceptions and stigma surrounding diabetes may discourage patients from seeking medical advice or properly managing their condition. The healthcare system’s capacity to offer comprehensive diabetes education and support remains underdeveloped in certain areas, particularly outside urban centers. Without adequate patient education, there is a higher likelihood of non-adherence to insulin regimens, which can lead to poor disease control and an increased risk of complications. Overcoming these educational barriers is essential for ensuring better diabetes management and improving the overall effectiveness of insulin therapy in Indonesia.
Market Opportunities
The human insulin market in Indonesia presents significant opportunities for growth, driven by the increasing prevalence of diabetes and the rising demand for affordable and effective treatment options. With the diabetic population continuing to expand, there is a growing need for accessible insulin products, particularly in rural and underserved areas. The Indonesian government’s efforts to improve healthcare access, including the expansion of healthcare insurance and subsidies for essential medications, create a favorable environment for market growth. Additionally, the demand for insulin is expected to rise as more patients in both urban and rural areas gain better access to diabetes care, creating an opportunity for companies to expand their reach through local production and distribution channels. The shift towards more affordable biosimilar insulin products also presents a significant opportunity to capture a larger share of the market, offering cost-effective alternatives to branded insulins without compromising on quality.
Another key opportunity lies in the growing adoption of advanced insulin delivery devices, such as insulin pens, pumps, and digital monitoring tools. These devices offer increased convenience, accuracy, and adherence to treatment regimens, making them particularly attractive for patients with chronic diabetes. The rising trend of personalized diabetes care further enhances the potential for innovation in insulin delivery systems. Additionally, as healthcare awareness improves across the country, patients are becoming more proactive in managing their condition, presenting an opportunity for companies to invest in educational programs and digital platforms that support self-management. By aligning their product offerings with these trends and addressing the unique needs of the Indonesian market, companies can capitalize on the growing demand for insulin products and expand their market presence.
Market Segmentation Analysis:
By Device:
The Indonesian human insulin market can be segmented based on the device used for insulin administration, which includes pens, syringes, and others. Insulin pens have become the preferred device for a growing number of diabetic patients due to their ease of use, portability, and convenience, particularly among patients who need to administer insulin multiple times a day. The rise in patient preference for pens over syringes is also supported by advancements in insulin delivery technology, which ensure more accurate and comfortable injections. Insulin syringes still hold a significant share of the market, especially among older patients or those in lower-income segments who may find syringes more affordable. However, the adoption of syringes is gradually declining as patients shift to more user-friendly alternatives. Additionally, the “Others” category includes insulin pumps and prefilled syringes, which are gaining traction due to their precision and ability to provide continuous insulin delivery. These devices cater to a more specific patient base but are expected to grow with increasing demand for advanced diabetes management tools.
By Indication:
In terms of indication, the human insulin market in Indonesia can be segmented into Type 1 diabetes, Type 2 diabetes, and gestational diabetes. Type 2 diabetes holds the largest share of the market, driven by the rising prevalence of lifestyle-related risk factors such as obesity and physical inactivity. This segment is expanding rapidly as the population ages and the disease burden increases. Type 1 diabetes, though less common, also represents a significant portion of the insulin market, with patients requiring lifelong insulin therapy for proper disease management. Gestational diabetes, which affects pregnant women, is another growing segment as awareness of the condition increases. While it is typically temporary, gestational diabetes requires careful management to prevent complications, leading to a steady demand for insulin during pregnancy. As healthcare access improves across the country, all three segments are expected to experience growth, providing ample opportunities for insulin suppliers to cater to diverse patient needs.
Segments:
Based on Device:
Pens
Syringes
Others
Based on Indication:
Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
Based on Insulin:
Rapid-acting insulin
Short-acting insulin
Intermediate-acting insulin
Others
Based on Distribution Channel:
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
Based on the Geography:
Java
Sumatra
Kalimantan
Sulawesi
Regional Analysis
Java
Java holds the dominant market share, accounting for approximately 60% of the total insulin consumption in Indonesia. This can be attributed to Java’s highly urbanized population, with cities such as Jakarta and Surabaya acting as economic hubs, leading to higher diabetes prevalence and consequently, increased demand for insulin. The region’s healthcare infrastructure is robust, with a significant number of hospitals and clinics offering advanced diabetes care, which further drives insulin usage.
Sumatra
Sumatra, with a market share of 20%, follows Java in insulin consumption. The region is characterized by a growing diabetic population, fueled by urbanization and lifestyle changes. While Sumatra is less urbanized compared to Java, it is still a vital market for insulin due to the presence of several large cities like Medan and Palembang. The availability of healthcare services and government initiatives aimed at enhancing healthcare access have positively impacted insulin accessibility. As the region continues to develop, it is expected that the demand for human insulin will rise steadily in line with economic growth and improving healthcare infrastructure.
Kalimantan
Kalimantan, accounting for about 10% of Indonesia’s human insulin market, shows a slower but steady growth in insulin consumption. The region’s relatively lower population density and lesser number of healthcare facilities have historically led to lower insulin demand. However, as Kalimantan experiences gradual urbanization and the government invests in expanding healthcare services, there is an upward trend in the consumption of insulin. The growing awareness of diabetes, particularly in urban areas like Banjarmasin, is contributing to this trend, and as the region’s healthcare infrastructure improves, the demand for insulin is projected to increase.
Sulawesi
Sulawesi represents the smallest share of the market, with an approximate 5% market share. The island’s relatively lower urbanization and healthcare availability have constrained insulin access and usage. However, efforts by the government to improve healthcare services and infrastructure are gradually addressing these challenges. Cities like Makassar are witnessing increased awareness campaigns and the availability of insulin, contributing to the slowly growing market share. With continued economic development and healthcare improvements, Sulawesi’s demand for human insulin is expected to see incremental growth in the coming years.
Key Player Analysis
Novo Nordisk A/S
MannKind Corporation
Pfizer
Wockhardt
Biocon
Lupin
Tonghua Dongbao Pharmaceutical Co
Eli Lilly and Company
Bio Farma
Competitive Analysis
The competitive landscape of Indonesia’s human insulin market is dominated by a mix of global and local players, each striving to meet the growing demand for insulin amidst an increasing diabetic population. Leading multinational companies such as Novo Nordisk, Eli Lilly and Company, and Pfizer play a significant role due to their established market presence and extensive distribution networks. These companies benefit from well-established distribution networks, allowing them to reach both urban and rural populations across Indonesia.
Local players, on the other hand, play a critical role in addressing the demand for affordable insulin. Their ability to provide cost-effective solutions tailored to the Indonesian market has given them an edge in catering to a significant portion of the population. Many local manufacturers are also supported by government initiatives aimed at enhancing healthcare access and reducing the cost burden of diabetes treatment. With the increasing prevalence of diabetes, competition has intensified, prompting players to innovate. This includes advancements in insulin delivery systems, such as insulin pens and biosimilar insulin products, which help meet the diverse needs of patients. As healthcare infrastructure continues to improve and the diabetic population grows, competition in Indonesia’s human insulin market is expected to remain fierce, with both local and international companies striving to capture a larger share of the market.
Recent Developments
In April 2025, Novo Nordisk announced the discontinuation of Human Mixtard, India’s largest-selling human insulin brand, as part of a global strategy to prioritize newer, patented diabetes and weight loss therapies such as Ozempic and Wegovy. While vial forms of Mixtard, Actrapid, and Insulatard will remain available, pen devices (Penfills and FlexPens) are being phased out, which is expected to disrupt patient access and preference in India.
In April 2025, Pfizer discontinued the development of danuglipron, its once-daily oral GLP-1 receptor agonist for obesity and type 2 diabetes, following a case of drug-induced liver injury and after reviewing clinical and regulatory feedback. This decision halts further clinical development for both obesity and diabetes indications.
In March 2025, Biocon Biologics entered a strategic collaboration with Civica, Inc. to expand access to Insulin Aspart in the United States. Biocon will supply the drug substance, which Civica will formulate and commercialize after completing development and clinical trials.
In December 2024, Lupin acquired the Huminsulin® portfolio in India from Eli Lilly and Company. The range includes Insulin Human (Huminsulin R, NPH, 50/50, and 30/70) and is indicated for type 1 and type 2 diabetes. Lupin had previously marketed these products under a distribution agreement, and the acquisition is aimed at strengthening its diabetes portfolio.
In November 2024, MannKind’s Afrezza® (insulin human) Inhalation Powder received approval from India’s CDSCO. MannKind expects to ship product to its partner Cipla by the end of 2025.
In October 2024, Wockhardt filed for approval of its fast-acting insulin analog, Aspart injection (ASPARAPID™), with the Drugs Controller General of India (DCGI). The product, developed indigenously, will be offered in cartridges, vials, and prefilled disposable pens. This expands Wockhardt’s diabetes biosimilars portfolio and addresses a market with limited competition.
Market Concentration & Characteristics
The market concentration of Indonesia’s human insulin sector is relatively moderate, with a mix of dominant multinational companies and emerging local players. The industry is characterized by a few large global companies that control a significant portion of the market due to their established reputations, extensive product offerings, and robust distribution networks. These multinational corporations benefit from economies of scale, allowing them to offer a wide range of insulin products, including long-acting, rapid-acting, and biosimilar insulin. However, local players also contribute substantially, particularly in providing cost-effective alternatives for the domestic market. The increasing prevalence of diabetes in Indonesia has led to heightened competition, fostering product innovation, especially in insulin delivery systems such as pens and pumps. The market is also shaped by government policies aimed at improving access to insulin, particularly in rural and underserved areas. As healthcare infrastructure expands, the market dynamics are shifting towards greater affordability and improved patient access.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
The research report offers an in-depth analysis based on Device,Indication, Insulin,Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
The demand for human insulin in Indonesia is expected to rise steadily due to the increasing prevalence of diabetes.
Growth in healthcare infrastructure, particularly in rural regions, will improve access to insulin and diabetes care.
Advances in insulin delivery systems, such as pens and pumps, will make treatment more convenient for patients.
The market will see a rise in the availability of biosimilar insulins, making treatment more affordable.
The government’s focus on improving healthcare access and affordability will drive insulin consumption in underserved areas.
Local production of insulin will increase, reducing dependency on imports and potentially lowering costs.
Rising awareness and education about diabetes will lead to earlier diagnosis and a greater need for insulin therapy.
More partnerships between local manufacturers and global players are likely to expand market reach and product offerings.
The increasing number of diabetic patients in Indonesia will result in heightened competition among insulin providers.
The market is expected to benefit from a shift towards personalized diabetes care, with treatments tailored to individual patient needs.
CHAPTER NO. 1 : INTRODUCTION 19
1.1.1. Report Description 19 Purpose of the Report 19 USP & Key Offerings 19
1.1.2. Key Benefits for Stakeholders 19
1.1.3. Target Audience 20
1.1.4. Report Scope 20 CHAPTER NO. 2 : EXECUTIVE SUMMARY 21
2.1. Human Insulin Market Snapshot 21
2.1.1. Indonesia Human Insulin Market, 2018 – 2032 (USD Million) 22 CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 23
3.1. Russia-Ukraine and Israel-Palestine War Impacts 23 CHAPTER NO. 4 : HUMAN INSULIN MARKET – INDUSTRY ANALYSIS 24
4.1. Introduction 24
4.2. Market Drivers 25
4.2.1. Driving Factor 1 Analysis 25
4.2.2. Driving Factor 2 Analysis 26
4.3. Market Restraints 27
4.3.1. Restraining Factor Analysis 27
4.4. Market Opportunities 28
4.4.1. Market Opportunity Analysis 28
4.5. Porter’s Five Forces Analysis 29
4.6. Value Chain Analysis 30
4.7. Buying Criteria 31 CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 32
5.1. Import Analysis by Indonesia 32
5.1.1. Indonesia Human Insulin Market Import Volume/Revenue, By Indonesia, 2018 – 2023 32
5.2. Export Analysis by Indonesia 33
5.2.1. Indonesia Human Insulin Market Export Volume/Revenue, By Indonesia, 2018 – 2023 33 CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 34
6.1. Demand Analysis by Indonesia 34
6.1.1. Indonesia Human Insulin Market Demand Volume/Revenue, By Indonesia, 2018 – 2023 34
6.2. Supply Analysis by Indonesia 35
6.2.1. Indonesia Human Insulin Market Supply Volume/Revenue, By Indonesia, 2018 – 2023 35 CHAPTER NO. 7 : PRODUCTION ANALYSIS 36
7.1. Production Analysis by Indonesia 36
7.1.1. Indonesia Human Insulin Market Production Volume/Revenue, By Indonesia, 2018 – 2023 36 CHAPTER NO. 8 : PRICE ANALYSIS 37
8.1. Price Analysis by Type 37
8.1.1. Indonesia Human Insulin Market Price, By Type, 2018 – 2023 37
8.1.2. Indonesia Type Market Price, By Type, 2018 – 2023 37 CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 38
9.1. Key Raw Materials and Suppliers 38
9.2. Key Raw Materials Price Trend 38 CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 39
10.1. Manufacturing Cost Analysis 39
10.2. Manufacturing Process 39 CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 40
11.1. Company Market Share Analysis – 2023 40
11.1.1. Indonesia Human Insulin Market: Company Market Share, by Volume, 2023 40
11.1.2. Indonesia Human Insulin Market: Company Market Share, by Revenue, 2023 41
11.1.3. Indonesia Human Insulin Market: Top 6 Company Market Share, by Revenue, 2023 41
11.1.4. Indonesia Human Insulin Market: Top 3 Company Market Share, by Revenue, 2023 42
11.2. Indonesia Human Insulin Market Company Volume Market Share, 2023 43
11.3. Indonesia Human Insulin Market Company Revenue Market Share, 2023 44
11.4. Company Assessment Metrics, 2023 45
11.4.1. Stars 45
11.4.2. Emerging Leaders 45
11.4.3. Pervasive Players 45
11.4.4. Participants 45
11.5. Start-ups /SMEs Assessment Metrics, 2023 45
11.5.1. Progressive Companies 45
11.5.2. Responsive Companies 45
11.5.3. Dynamic Companies 45
11.5.4. Starting Blocks 45
11.6. Strategic Developments 46
11.6.1. Acquisitions & Mergers 46 New Product Launch 46 Indonesia Expansion 46
11.7. Key Players Product Matrix 47 CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 48
12.1. PESTEL 48
12.1.1. Political Factors 48
12.1.2. Economic Factors 48
12.1.3. Social Factors 48
12.1.4. Technological Factors 48
12.1.5. Environmental Factors 48
12.1.6. Legal Factors 48
12.2. Adjacent Market Analysis 48 CHAPTER NO. 13 : HUMAN INSULIN MARKET – BY TYPE SEGMENT ANALYSIS 49
13.1. Human Insulin Market Overview, by Type Segment 49
13.1.1. Human Insulin Market Revenue Share, By Type, 2023 & 2032 50
13.1.2. Human Insulin Market Attractiveness Analysis, By Type 51
13.1.3. Incremental Revenue Growth Opportunity, by Type, 2024 – 2032 51
13.1.4. Human Insulin Market Revenue, By Type, 2018, 2023, 2027 & 2032 52
13.2. Pens 53
13.3. Syringes 54
13.4. Others 55
13.5. Type 4 56
13.6. Type 5 57 CHAPTER NO. 14 : HUMAN INSULIN MARKET – BY APPLICATION SEGMENT ANALYSIS 58
14.1. Human Insulin Market Overview, by Application Segment 58
14.1.1. Human Insulin Market Revenue Share, By Application, 2023 & 2032 59
14.1.2. Human Insulin Market Attractiveness Analysis, By Application 60
14.1.3. Incremental Revenue Growth Opportunity, by Application, 2024 – 2032 60
14.1.4. Human Insulin Market Revenue, By Application, 2018, 2023, 2027 & 2032 61
14.2. Type 1 Diabetes 62
14.3. Type 2 Diabetes 63
14.4. Gestational Diabetes 64
14.5. Application 4 65
14.6. Application 5 66 CHAPTER NO. 15 : HUMAN INSULIN MARKET – BY END-USER SEGMENT ANALYSIS 67
15.1. Human Insulin Market Overview, by End-user Segment 67
15.1.1. Human Insulin Market Revenue Share, By End-user, 2023 & 2032 68
15.1.2. Human Insulin Market Attractiveness Analysis, By End-user 69
15.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 69
15.1.4. Human Insulin Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70
15.2. Rapid-acting insulin 71
15.3. Short-acting insulin 72
15.4. Intermediate-acting insulin 73
15.5. Others 74
15.6. End-user 5 75 CHAPTER NO. 16 : HUMAN INSULIN MARKET – BY TECHNOLOGY SEGMENT ANALYSIS 76
16.1. Human Insulin Market Overview, by Technology Segment 76
16.1.1. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 77
16.1.2. Human Insulin Market Attractiveness Analysis, By Technology 78
16.1.3. Incremental Revenue Growth Opportunity, by Technology, 2024 – 2032 78
16.1.4. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79
16.2. Technology 1 80
16.3. Technology 2 81
16.4. Technology 3 82 CHAPTER NO. 17 : – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 83
17.1. Human Insulin Market Overview, by Distribution Channel Segment 83
17.1.1. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 84
17.1.2. Human Insulin Market Attractiveness Analysis, By Distribution Channel 85
17.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 85
17.1.4. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86
17.2. Hospital Pharmacies 87
17.3. Drug Stores and Retail Pharmacies 88
17.4. Online Providers 89
17.5. Distribution Channel 4 90
17.6. Distribution Channel 5 91 CHAPTER NO. 18 : HUMAN INSULIN MARKET – INDONESIA ANALYSIS 92
18.1. Type 92
18.1.1. Indonesia Human Insulin Market Revenue, By Type, 2018 – 2023 (USD Million) 92
18.2. Indonesia Human Insulin Market Revenue, By Type, 2024 – 2032 (USD Million) 92
18.3. Application 93
18.3.1. Indonesia Human Insulin Market Revenue, By Application, 2018 – 2023 (USD Million) 93
18.3.2. Indonesia Human Insulin Market Revenue, By Application, 2024 – 2032 (USD Million) 93
18.4. End-user 94
18.4.1. Indonesia Human Insulin Market Revenue, By End-user, 2018 – 2023 (USD Million) 94
18.4.2. Indonesia Human Insulin Market Revenue, By End-user, 2024 – 2032 (USD Million) 94
18.5. Technology 95
18.5.1. Indonesia Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 95
18.5.2. Indonesia Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 95
18.6. Distribution Channel 96
18.6.1. Indonesia Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 96
18.6.2. Indonesia Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 96 CHAPTER NO. 19 : COMPANY PROFILES 97
19.1. Novo Nordisk A/S 97
19.1.1. Company Overview 97
19.1.2. Product Portfolio 97
19.1.3. Swot Analysis 97
19.1.4. Business Strategy 98
19.1.5. Financial Overview 98
19.1.6. MannKind Corporation 99
19.1.7. Pfizer 99
19.1.8. Wockhardt 99
19.1.9. Biocon 99
19.1.10. Lupin 99
19.1.11. Tonghua Dongbao Pharmaceutical Co 99
19.1.12. Eli Lilly and Company 99
19.1.13. Bio Farma 99
19.1.14. Company 10 99
19.1.15. Company 11 99
19.1.16. Company 12 99
19.1.17. Company 13 99
19.1.18. Company 14 99 CHAPTER NO. 20 : RESEARCH METHODOLOGY 100
20.1. Research Methodology 100
20.1.1. Phase I – Secondary Research 101
20.1.2. Phase II – Data Modeling 101 Company Share Analysis Model 102 Revenue Based Modeling 102
20.1.3. Phase III – Primary Research 103
20.1.4. Research Limitations 104 Assumptions 104 List of Figures
FIG NO. 1. Indonesia Human Insulin Market Revenue, 2018 – 2032 (USD Million) 22
FIG NO. 2. Porter’s Five Forces Analysis for Indonesia Human Insulin Market 29
FIG NO. 3. Value Chain Analysis for Indonesia Human Insulin Market 30
FIG NO. 4. Indonesia Human Insulin Market Import Volume/Revenue, By Indonesia, 2018 – 2023 32
FIG NO. 5. Indonesia Human Insulin Market Export Volume/Revenue, By Indonesia, 2018 – 2023 33
FIG NO. 6. Indonesia Human Insulin Market Demand Volume/Revenue, By Indonesia, 2018 – 2023 34
FIG NO. 7. Indonesia Human Insulin Market Supply Volume/Revenue, By Indonesia, 2018 – 2023 35
FIG NO. 8. Indonesia Human Insulin Market Production Volume/Revenue, By Indonesia, 2018 – 2023 36
FIG NO. 9. Indonesia Human Insulin Market Price, By Type, 2018 – 2023 37
FIG NO. 10. Raw Materials Price Trend Analysis, 2018 – 2023 38
FIG NO. 11. Manufacturing Cost Analysis 39
FIG NO. 12. Manufacturing Process 39
FIG NO. 13. Company Share Analysis, 2023 40
FIG NO. 14. Company Share Analysis, 2023 41
FIG NO. 15. Company Share Analysis, 2023 41
FIG NO. 16. Company Share Analysis, 2023 42
FIG NO. 17. Human Insulin Market – Company Volume Market Share, 2023 43
FIG NO. 18. Human Insulin Market – Company Revenue Market Share, 2023 44
FIG NO. 19. Human Insulin Market Revenue Share, By Type, 2023 & 2032 50
FIG NO. 20. Market Attractiveness Analysis, By Type 51
FIG NO. 21. Incremental Revenue Growth Opportunity by Type, 2024 – 2032 51
FIG NO. 22. Human Insulin Market Revenue, By Type, 2018, 2023, 2027 & 2032 52
FIG NO. 23. Indonesia Human Insulin Market for Pens, Revenue (USD Million) 2018 – 2032 53
FIG NO. 24. Indonesia Human Insulin Market for Syringes, Revenue (USD Million) 2018 – 2032 54
FIG NO. 25. Indonesia Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 55
FIG NO. 26. Indonesia Human Insulin Market for Type 4, Revenue (USD Million) 2018 – 2032 56
FIG NO. 27. Indonesia Human Insulin Market for Type 5, Revenue (USD Million) 2018 – 2032 57
FIG NO. 28. Human Insulin Market Revenue Share, By Application, 2023 & 2032 59
FIG NO. 29. Market Attractiveness Analysis, By Application 60
FIG NO. 30. Incremental Revenue Growth Opportunity by Application, 2024 – 2032 60
FIG NO. 31. Human Insulin Market Revenue, By Application, 2018, 2023, 2027 & 2032 61
FIG NO. 32. Indonesia Human Insulin Market for Type 1 Diabetes, Revenue (USD Million) 2018 – 2032 62
FIG NO. 33. Indonesia Human Insulin Market for Type 2 Diabetes, Revenue (USD Million) 2018 – 2032 63
FIG NO. 34. Indonesia Human Insulin Market for Gestational Diabetes, Revenue (USD Million) 2018 – 2032 64
FIG NO. 35. Indonesia Human Insulin Market for Application 4, Revenue (USD Million) 2018 – 2032 65
FIG NO. 36. Indonesia Human Insulin Market for Application 5, Revenue (USD Million) 2018 – 2032 66
FIG NO. 37. Human Insulin Market Revenue Share, By End-user, 2023 & 2032 68
FIG NO. 38. Market Attractiveness Analysis, By End-user 69
FIG NO. 39. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 69
FIG NO. 40. Human Insulin Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70
FIG NO. 41. Indonesia Human Insulin Market for Rapid-acting insulin, Revenue (USD Million) 2018 – 2032 71
FIG NO. 42. Indonesia Human Insulin Market for Short-acting insulin, Revenue (USD Million) 2018 – 2032 72
FIG NO. 43. Indonesia Human Insulin Market for Intermediate-acting insulin, Revenue (USD Million) 2018 – 2032 73
FIG NO. 44. Indonesia Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 74
FIG NO. 45. Indonesia Human Insulin Market for End-user 5, Revenue (USD Million) 2018 – 2032 75
FIG NO. 46. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 77
FIG NO. 47. Market Attractiveness Analysis, By Technology 78
FIG NO. 48. Incremental Revenue Growth Opportunity by Technology, 2024 – 2032 78
FIG NO. 49. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79
FIG NO. 50. Indonesia Human Insulin Market for Technology 1, Revenue (USD Million) 2018 – 2032 80
FIG NO. 51. Indonesia Human Insulin Market for Technology 2, Revenue (USD Million) 2018 – 2032 81
FIG NO. 52. Indonesia Human Insulin Market for Technology 3, Revenue (USD Million) 2018 – 2032 82
FIG NO. 53. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 84
FIG NO. 54. Market Attractiveness Analysis, By Distribution Channel 85
FIG NO. 55. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 85
FIG NO. 56. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86
FIG NO. 57. Indonesia Human Insulin Market for Hospital Pharmacies, Revenue (USD Million) 2018 – 2032 87
FIG NO. 58. Indonesia Human Insulin Market for Drug Stores and Retail Pharmacies, Revenue (USD Million) 2018 – 2032 88
FIG NO. 59. Indonesia Human Insulin Market for Online Providers, Revenue (USD Million) 2018 – 2032 89
FIG NO. 60. Indonesia Human Insulin Market for Distribution Channel 4, Revenue (USD Million) 2018 – 2032 90
FIG NO. 61. Indonesia Human Insulin Market for Distribution Channel 5, Revenue (USD Million) 2018 – 2032 91
FIG NO. 62. Research Methodology – Detailed View 100
FIG NO. 63. Research Methodology 101
List of Tables
TABLE NO. 1. : Indonesia Human Insulin Market: Snapshot 18
TABLE NO. 2. : Drivers for the Human Insulin Market: Impact Analysis 22
TABLE NO. 3. : Restraints for the Human Insulin Market: Impact Analysis 24
TABLE NO. 4. : Indonesia Human Insulin Market Revenue, By Type, 2018 – 2023 34
TABLE NO. 5. : Key Raw Materials & Suppliers 35
TABLE NO. 6. : Indonesia Human Insulin Market Revenue, By Type, 2018 – 2023 (USD Million) 89
TABLE NO. 7. : Indonesia Human Insulin Market Revenue, By Type, 2024 – 2032 (USD Million) 89
TABLE NO. 8. : Indonesia Human Insulin Market Revenue, By Application, 2018 – 2023 (USD Million) 90
TABLE NO. 9. : Indonesia Human Insulin Market Revenue, By Application, 2024 – 2032 (USD Million) 90
TABLE NO. 10. : Indonesia Human Insulin Market Revenue, By End-user, 2018 – 2023 (USD Million) 91
TABLE NO. 11. : Indonesia Human Insulin Market Revenue, By End-user, 2024 – 2032 (USD Million) 91
TABLE NO. 12. : Indonesia Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 92
TABLE NO. 13. : Indonesia Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 92
TABLE NO. 14. : Indonesia Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 93
TABLE NO. 15. : Indonesia Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 93
Frequently Asked Questions:
What is the current size of the Indonesia Human Insulin?
The market was valued at USD 128.30 million in 2023 and is projected to reach USD 181.63 million by 2032.
What factors are driving the growth of the Indonesia Human Insulin?
Key drivers include rising diabetes prevalence, technological advancements in insulin delivery, and supportive government healthcare initiatives.
What are the key segments within the Indonesia Human Insulin?
The market is segmented by Device (Pens, Syringes, Others), Indication (Type 1, Type 2, Gestational Diabetes), Insulin Type, Distribution Channel, and Geography.
What are some challenges faced by the Indonesia Human Insulin?
Challenges include limited access in rural areas and high insulin costs despite growing demand.
Who are the major players in the Indonesia Human Insulin?
Key players include Novo Nordisk, Eli Lilly, Bio Farma, Pfizer, Biocon, and Wockhardt.
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing.
$2699
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis and multi-location access, making it an excellent choice for organizations with distributed workforce.
$3699
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc.’s research team. It is highly recommended for organizations seeking to execute short, customized research projects related to the scope of the purchased report.
I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.
